Gilead Sciences (NASDAQ:GILD) is set to report its first-quarter earnings on Thursday, April 24th, after the market closes.

Wesley Sundquist, a biochemist at the University of Utah, was recently featured in Time's annual "100 Most Influential People ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

The discovery of a highly efficacious option for preexposure prophylaxis that requires only twice-yearly administration has led to the question of whether a vaccine is still needed to end the HIV ...

The medicine, lenacapavir, made by Gilead Sciences, has caused a stir because clinical trial data showed a single set of injections every six months could provide virtually complete protection ...

Before losing her job at USAID, Katomski’s research division was considering trials for lenacapavir, the 2024 “breakthrough” drug. “All of that’s just been cut off,” she says.

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and ...